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Exposures to Pharmaceutical Dust at a Mail Order Pharmacy
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INTRODUCTION
Mail order pharmacies are the fastest growing sector of the U.S. prescription drug retail 
market. In 2004, they accounted for 6.1% of all prescriptions filled, which was an 18% 
increase over the previous year.(1) Although large volumes of prescriptions are filled at mail 
order pharmacies, the potential for employee exposures to pharmaceutical dust has not been 
fully evaluated. In 2010, the National Institute for Occupational Safety and Health (NIOSH) 
received a health hazard evaluation request from managers at a mail order pharmacy 
concerning potential pharmaceutical dust exposures to employees.
The mail order pharmacy was divided into two areas: (1) the pharmacy, where automatic 
dispensing machines were located and most prescriptions were filled, and (2) the warehouse, 
where other activities such as manual counting and replenishment of canisters were 
performed. Two brands of automatic dispensing machines were used for filling high 
throughput prescriptions: Baker (one large customized machine made by McKesson 
Corporation, San Francisco, Calif.) and Optifill (two smaller customized machines made by 
AmerisourceBergen, Valley Forge, Pa.). All three machines used gravity to dispense 
pharmaceutical tablets and capsules.
The Baker machine had an elevated platform where the canisters containing pharmaceuticals 
were loaded into the machine. The pharmaceuticals were fed from a canister into a cell 
below the platform. A conveyor belt on the outside of the machine carried a prescription 
bottle to the nozzle below the appropriate cell, and a valve in the cell opened to dispense the 
pharmaceutical into the bottle. The Baker machine filled approximately 10,000 prescriptions 
per day. Two pharmacy technicians maintained the Baker machine. Their responsibilities 
included freeing jams, identifying bottles that were not filled, and cleaning and repairing 
malfunctioning cells. The Baker canisters were refilled in the offline replenishment area in 
the warehouse where two or three pharmacy technicians dumped the appropriate 
pharmaceuticals from the original manufacturer packaged bottles into a funnel that fed into a 
labeled Baker canister.
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Canisters were situated on the outside of each of the two Optifill machines. A conveyor belt 
carried prescription bottles through the middle of either machine. A bottle stopped below 
one of the eight shared chutes in each machine. A canister dispensed the appropriate 
pharmaceutical into the chute that funneled into the bottle. The Optifill machines filled 
approximately 2000 prescriptions per day. Two pharmacy technicians replenished and 
repaired the Optifill canisters, which were then verified by a pharmacist.
Pharmacy technicians also filled prescriptions by hand in the special handling, hazardous 
drug, or manual count areas in the warehouse. Hazardous drugs are drugs known or 
suspected to cause adverse health effects from exposures in the workplace.(2,3) Warfarin was 
the primary pharmaceutical dispensed in the special handling area, while a variety of other 
pharmaceuticals were dispensed in the manual count areas. Baker canisters were also 
routinely cleaned in the warehouse using mainly detergent and water.
Use of personal protective equipment was sporadic among employees and included vinyl 
examination gloves or nitrile gloves, N95 filtering facepiece respirators, hair caps, and cloth 
aprons. We did not observe the presence or use of local exhaust ventilation for any of the 
processes.
METHODS
We conducted a multi-metric evaluation (1) to determine if and during which activities dust 
was released into the air, (2) to measure the concentration of the airborne dust, (3) to 
determine if the airborne dust contained pharmaceuticals, and (4) to identify and quantify 
specific active pharmaceutical ingredients (APIs) in the airborne dust. We visited the facility 
in April and December 2010. The information gathered during the first visit was used to 
develop our sampling methodology for the second visit. Here we present the methods and 
results of the second visit that took place over 3 days in December 2010. For complete 
results, see the health hazard evaluation report available at http://www.cdc.gov/niosh/hhe/
reports/pdfs/2010-0026-3150.pdf.
We collected 25 each of total dust (37-mm-diameter closed-face cassette, 4 L/min) and 
inhalable dust (25-mm-diameter Institute of Medicine cassette, 2 L/min) air samples on 11 
employees. Samples were positioned side-by-side in the employees’ personal breathing zone 
(PBZ) and collected over the entire work shift (approximately 8 hr). Both the total and 
inhalable dust samplers contained tared polytetrafluoroethylene filters (1-μm pore size) that 
were analyzed gravimetrically. Due to its larger inlet, an inhalable dust sample collects more 
particles >30 μm in aerodynamic diameter than a closed-face total dust sample.(4)
Real-time particle count measurements were collected using an HHPC-6 (Hach Ultra 
Analytics, Inc., Loveland, Colo.) near the PBZs of the employees to identify specific tasks 
that resulted in increased particle counts (Figure 1). The types of tablets that were handled 
during these dust-releasing tasks were recorded. Managers and employees at the pharmacy 
also provided us with a list of tablets that were friable. Such tablets were uncoated mainly 
and, in many cases, were the generic version of a brand name pharmaceutical. Using this 
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information, we generated lists of APIs that could potentially be present on each total or 
inhalable dust sample filter.
Figure 2 shows the progression of the other analyses done on the total and inhalable dust 
sample filters after they were analyzed gravimetrically. We quantified lactose, a common 
inactive ingredient in pharmaceuticals, on the inhalable dust sample filters using an 
analytical method developed by BureauVeritas (Novi, Mich.). Total dust sample filters were 
analyzed using a desorption electrospray ionization/mass spectrometry (DESI/MS) system(5) 
to identify specific APIs on the filters by cross referencing mass-to-charge ratios with the 
lists of APIs handled at the facility. Four total dust sample filters were not further analyzed 
because we did not have information to indicate which APIs could be present on them.
We selected five inhalable dust samples for quantitation of lisinopril, which was chosen 
because the analytical method developed by Bureau Veritas required dissolution in water, 
and the inhalable dust samples were already dissolved in water for the lactose analysis. In 
addition, lisinopril has a relatively low manufacturer’s exposure control band of 1 to <10 
μg/m3.(6) We also selected two total dust air samples for quantitation of warfarin using 
NIOSH Method 5002.(7) We chose to analyze for warfarin because it was the predominant 
drug handled by the employees in the special handling area. The analytical methods for 
lactose and lisinopril are summarized in the health hazard evaluation report. We used 
Microsoft Excel for performing basic statistics.
RESULTS
Peaks in particle counts were observed during the cleaning of Baker cells and replenishment 
of Baker canisters (data not shown). Using our recorded observations, we identified the APIs 
that were handled during these peaks in particle counts. Figure 3 summarizes the PBZ 
inhalable dust (ranging from 110–800 μg/m3), total dust (ranging from 6–260 μg/m3), and 
lactose concentrations (ranging from 0.94–63 μg/m3) by process and location; standard 
deviations are represented by error bars. Area air concentrations (measured in the non-
production areas of the pharmacy) are also included in Figure 3 to show the relatively low 
background levels of dust and lactose. Area air concentrations of lactose in the non-
production areas of the pharmacy were significantly lower (P < 0.001) than the PBZ 
concentrations measured on employees in the production areas.
The average inhalable dust concentrations were 1.3 to 3.7 times higher than the average total 
dust concentrations measured on the same employees. The highest average total and 
inhalable dust exposures were measured in the PBZs of employees who did offline 
replenishment of Baker canisters, hand filling of prescriptions (manual count), online 
replenishment of Optifill canisters, and cleaning of Baker cells. Employees doing these 
tasks, as well as the hand filling of prescriptions (special handling), also had the highest 
average PBZ concentrations of lactose.
APIs were detected on 17 of 19 total dust sample filters analyzed by DESI/MS. The 17 APIs 
identified on these filters are shown in Table I. Five other APIs were identified on three total 
dust sample filters collected during the first visit (data not shown). The PBZ concentrations 
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of warfarin (n = 2), measured during the hand filling of warfarin prescriptions (special 
handling), ranged from 0.50–0.64 μg/m3. Similar levels (0.19–3.8 μg/m3, n = 3) were 
measured during the first visit. These levels are well below the NIOSH recommended 
exposure limit, the Occupational Safety and Health Administration permissible exposure 
limit, and the ACGIH® threshold limit value (TLV®) of 100 μg/m3.(8,9) Likewise, PBZ 
concentrations of lisinopril (n = 5), measured during different processes, ranged from non-
detectable to 0.44 μg/m3 and were well below the manufacturer’s exposure control band of 1 
to <10 μg/m3.(6)
DISCUSSION
The correlation of tasks (i.e., cleaning of Baker cells and replenishment of Baker canisters) 
with peaks in real-time particle counts suggests that pharmaceutical dust was released into 
the air where it could be inhaled by employees. Compared with a closed-face total dust 
sampler, an inhalable dust sampler, which has a larger inlet, has been shown to undersample 
particles larger than 30 μm in aerodynamic diameter.(4) Thus, the higher levels of inhalable 
dust compared with total dust suggest that some particles >30 μm in aerodynamic diameter 
were released. These larger particles settle quickly to the ground but when inhaled they are 
likely to be captured in the upper respiratory tract.(10) Although not presented here, 
respirable dust concentrations measured during the first visit were very low (at or below 
detection limits). Therefore, much of the pharmaceutical dust that was released probably did 
not stay suspended in the air for more than a few seconds. Hence, the inhalation exposure 
potential is likely far greater for the employees who undertake tasks that generate 
pharmaceutical dust than other employees (even those in the same general area). The highest 
PBZ concentrations of total dust, inhalable dust, and lactose were all measured on 
employees who performed duties that could generate pharmaceutical dust.
Occupational exposure limits (OELs) for general dust or particles not otherwise regulated 
are only applicable when the dust particles are biologically inert and are insoluble in 
water.(8) Pharmaceutical dust does not meet these criteria because APIs are designed to elicit 
biological responses, and most tablets are water soluble. Hence, inhalable pharmaceutical 
dust is biologically relevant because it can be absorbed anywhere in the respiratory system. 
Our data confirm that at least some of the dust we collected on air samples came from 
pharmaceuticals. Lactose, a common inactive ingredient in pharmaceuticals, was present in 
all inhalable dust air samples, and specific APIs were identified in most of the total dust air 
samples. The two APIs (warfarin and lisinopril) we selected for quantitation in air were 
present in one or more air samples, but the PBZ concentrations did not exceed their 
respective OEL or exposure control band.
The pharmacy stocked 61 hazardous drugs according to the NIOSH list,(3) 35 of which were 
tablets and therefore potentially capable of producing dust. Although we did not measure 
employee exposures during the hand filling of hazardous drug prescriptions, this process 
could present a substantial health risk to employees if proper safeguards are not in place. 
Exposures to hazardous drugs, even at low levels, can lead to serious health effects, 
including skin rashes, reproductive problems, and possibly cancer.(2) The pharmacy 
managers provided us with a copy of their standard operating procedures, which included 
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provisions for wearing gloves and cleaning up spills. No other control measures were listed. 
Although the guidelines in the NIOSH Alert, Preventing Occupational Exposure to 
Antineoplastic and Other Hazardous Drugs in Health Care Settings, are intended primarily 
for oncology clinics and hospital pharmacies, they could be adapted for this and other mail 
order pharmacies.
Ideally, we should have quantified PBZ concentrations to more of the APIs that we 
identified in air. However, we did not have access to analytical methods or manufacturer’s 
OELs for all of these APIs. Also, because APIs may require different extraction solvents, it 
is difficult to analyze for all APIs that might be collected on an air sample. Although 
pharmaceutical companies have established analytical methods and OELs or exposure 
control bands for many of the drugs they manufacture, not all are publicly available (e.g., 
provided in safety data sheets) or were provided to the mail order pharmacy we evaluated. 
Access to these methods and OELs or exposure control bands is necessary to conduct 
comprehensive exposure assessments in this growing industry. This information may be 
provided by manufacturers on request.
On the basis of the data we were able to gather, we believe it is prudent to reduce exposures 
during tasks that generate pharmaceutical dust. Employees who clean cells, replenish 
canisters, and hand fill prescriptions with friable tablets are potentially exposed to low levels 
of APIs that they are not prescribed. Some individuals may have allergies to specific APIs or 
take medications that could interact with APIs. Moreover, they are inhaling these APIs 
rather than ingesting them, which could change how the chemical affects the body. If 
exposed to multiple APIs, synergistic or additive health effects could be possible. In 
addition, pharmaceutical dust may settle on work surfaces and clothing. If employees do not 
wear gloves or wash hands before eating or using tobacco products as mandated, they could 
ingest APIs. Dermal absorption is also possible depending on the chemical makeup of APIs. 
For employees engaged in tasks that generate pharmaceutical dust, secondary exposure to 
family members may occur if personal clothing becomes contaminated with pharmaceutical 
dust and is worn at home. Children may be especially susceptible to adverse health effects 
from API exposures.(11)
We provided a number of recommendations to the mail order pharmacy managers to 
minimize pharmaceutical dust exposures. These recommendations included requiring 
employees to use local exhaust ventilation when cleaning cells, replenishing canisters, and 
hand filling hazardous drug prescriptions. We also recommended providing disposable 
gowns (or gowns that are kept at the pharmacy and professionally laundered) for employees 
to wear during work. The health hazard evaluation report provides a full list of our 
recommendations. However, further study is warranted to plan, implement, and test the 
efficacy of the recommended controls.
CONCLUSION
To our knowledge, this is the first evaluation of pharmaceutical dust exposures at a mail 
order pharmacy. Our data show that mail order pharmacy employees can be exposed to dust 
containing APIs, particularly when they clean cells, replenish canisters, or hand fill 
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prescriptions. More comprehensive evaluations are needed in this growing industry to 
determine the extent of exposures to APIs, including hazardous drugs, and to determine the 
best control measures and practices for minimizing such exposures.
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FIGURE 1. 
Using a real-time particle meter to measure particle counts near the PBZ of an employee 
cleaning a Baker cell
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FIGURE 2. 
Flow chart showing the subanalyses performed on the total and inhalable dust sample filters
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FIGURE 3. 
Summary of average work-shift PBZ concentrations of inhalable dust, total dust, and lactose 
by process and location. Error bars represent one standard deviation.
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